Intertek Group PLC
04 December 2006
04 December 2006, 7am (UK)
Intertek Group plc (Intertek) announces the acquisition of pharmaceutical
testing company Alta Analytical Laboratory Corporation (Alta)
Intertek, the leading international provider of quality and safety services to a
wide range of industries, announces that its Oil, Chemical and Agri division
(Caleb Brett) has acquired Alta for US$ 25.5 million (GBP 13.0 million) in cash
from the owner managers.
Alta supports North American pharmaceutical and clinical research organisations
by providing a variety of analytical services including the testing that is
required in the development of new drugs. The business, based out of two sites
in California, has over 100 employees and counts major global pharmaceutical
companies among its clients.
Wolfhart Hauser, Chief Executive Officer of Intertek, commented:
'We are delighted to announce this acquisition in the growing area of
pharmaceutical analysis. Alta's expertise and business gives us a platform to
build a global presence in this area, extending our existing European offering.'
Contacts
Aston Swift, Intertek
Telephone: +44 (0) 20 7396 3400
Aston.swift@intertek.com
Richard Mountain, Susanne Walker, Financial Dynamics
Telephone: +44 (0) 20 7831 3113
Richard.mountain@fd.com
High resolution images of Intertek Group plc businesses are available to
download, free of charge from www.vismedia.co.uk
About Intertek
Intertek (FTSE:ITRK) is a leading international provider of quality and safety
services to a wide range of global and local industries. Partnership with
Intertek brings increased value to customers' products and processes, ultimately
supporting their success in the global market place. Intertek has the
experience, expertise, resources and global reach to support its customers
through their network of 910 laboratories and offices, 17,400 people in 110
countries around the world.
www.intertek.com
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.